The c-kit proto-oncogene encodes a 145-to 160-Kd transmembrane tyrosine kinase, which is a member of the plateletderived growth factor receptor family and is allelic with the murine white spotting locus (W). W mutations affect several aspects of hematopoiesis, most notably erythroid progenitors and mast cells. A monoclonal antibody, YB5.B8, had been raised against the leukemic blasts of a patient with M,-type acute myelocytic leukemia (AML) and it precipitates a 150-Kd cell surface glycoprotein from leukemic cells. The YB5.BE epitope is expressed on mast cells, on up to 3% of normal mononuclear bone marrow cells, and it identifies a sub-group of AML patients with a poor prognosis. In view of similarities noted between the cell surface antigen identified by YB5.B8 and the c-kit protein product, we performed experiments t o determine whether they are identical. c-kit RNA expression in the cell lines HEL (human erythroleuke-HE c-kit proto-oncogene, the normal cellular homo-
mia) and A172 (glioblastoma) was shown t o parallel the expression of the YB5.BE epitope in these lines as measured by flow cytometry. Immunoprecipitation analysis with antikit serum and YB5.B8 antibody indicated that the two antibodies identified proteins of identical size in HEL (155 Kd) and A172 (145 Kd) cells, and sequential immunoprecipitations with the kit and the YB5.B8 antibodies demonstrated that the two antibodies recognize the same molecule. The proteins identified by both the anti-kit and YB5.BE antibodies displayed in vitro autophosphorylation activity in immune complex kinase assays. In addition, YB5.B8 was able t o inhibit the binding of the kit ligand t o HEL cells. These studies provide evidence that the YB5.B8 antigen and the c-kit protein product are identical and raise certain hypotheses regarding the role of e-kit in AML. 0 1991 b y The American Society of Hematology.
again suggesting a role for the c-kit receptor system in murine hematopoietic progenitors.8.16 While functions similar to those of the murine gene would be predicted for human c-kit, studies of the expression of the human c-kit gene products have been somewhat limited to date. High levels of c-kit mRNA expression have been demonstrated in two erythroleukemia cell lines, HEL and LAMA, and somewhat lower levels in the A172 glioblastoma cell line and term placenta.'." No detectable expression was seen in peripheral mononuclear cells and in myeloid and lymphoid cell lines.'3 c-kit mRNA expression has been reported in blast cell populations from patients with acute myelogenous leukemia (AML) but not in cells from patients with acute lymphoblastic leukemia (ALL) or in normal bone marrow." Studies of the effect of the c-kit ligand on human bone marrow showed that it synergized with other growth factors and thus implied that the c-kit receptor is operative in human hematopoietic progenitors."
A monoclonal antibody (MoAb), YBS.B8, had been raised against the leukemic blasts of a patient with M,-type AML and binds to cells from a subgroup of AML patients with poor progno~is.'~~*~ The YB5.B8 antigen is expressed on up to 3% of normal bone marrow cells, including hematopoietic progenitor cell populations capable of colony formation in vitro, and on connective tissue and mucosal-type mast cells.zl~" When included in in vitro colony assays, the YB5.B8 antibody causes a partial inhibition of colony formation, indicating a functional role for the YB5.BS antigen.*'^'' The YB5.B8 antibody precipitates a 145-to 150-Kd cell surface glycoprotein antigen from leukemic cells. '1,'4 In view of the similar (1) cellular distribution, (2) presumed functions in hematopoiesis, and (3) size of the cell surface antigen identified by YB5.B8, and that expressed by the c-kit proto-oncogene, we investigated whether these antigens are identical. Our studies show that the YB5.B8 antigen and the c-kit protein product are identical and suggest certain hypotheses regarding the role of c-kit in normal hematopoiesis and myelocytic leukemia.
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MATERIALS AND METHODS
Cells and culture conditions. The HEL (human erythroleukemia) cell line was obtained from the American Type Culture Collection (ATTC; Bethesda, MD)ZS and the Ramos cell line (Burkitt's lymphoma) and the A172 (glioblastoma) cell linez6 were obtained from the Human Tumor Cell Laboratory at Memorial Sloan Kettering Cancer Center (New York, NY). The HEL and Ramos cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), penicillin, streptomycin, nonessential amino acids, L-glutamine, sodium pyruvate, and 2-mercaptoethanol(5 x mol/L)." A172 cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% FCS. Bone marrow and peripheral blood samples were obtained from patients with various leukemias, especially AML, and from normal allogeneic transplant donors with informed consent. Cells were either immediately lysed in guanidinium isothiocyanate, according to the method of Chirgwin et alZ8 and frozen, or mononuclear cells were isolated by sedimentation in FicollHypaque and then cryopreserved." Thawed cells were treated as previously described.29
RNA from cell lines and from human bone marrow and peripheral blood samples was isolated according to the methods of Chirgwin et a12' or Chomczynski and Sacchi?' RNA blot analysis was performed as described previ0us1y.~ The final wash of hybridized filters was in 1X SSC (150 mmol/L sodium chloride, 15 mmol/L sodium citrate, pH 7.0) and 0.1% sodium dodecyl sulfate (SDS) at 65°C. A 1.25-kb fragment of the human c-kit cDNA (approximately 0 to 1.25 kb of the c-kit cDNA),' obtained from the ATTC, was labeled with "Pphosphate" and then used as a probe for hybridization.
The suspension cell lines HEL and Ramos were collected by low-speed centrifugation. Adherent A172 cells were incubated in phosphate-buffered saline (PBS) containing 0.6 mmol/L EDTA at 4°C for 1 hour and then detached from the culture dish with a rubber policeman and collected by low-speed centrifugation. All cells were then washed with medium (RPMI-1640) containing 5% FCS and 5% AB human serum (RPMI-CS-HS). Cells were labeled either with the MoAb YB5. HEL and A172 cells were incubated in methionine-free medium with 10% dialyzed FCS for 30 minutes at 37°C. Cells were then labeled with '3-methionine (500 pCi/mL) for 5 hours, washed in PBS at 4"C, and lysed in buffer containing 1% Triton X-100,20 mmol/L TRIS (pH 7.54, 150 mmoUL NaC1, 10% glycerol, and 5 mmol/L EDTA and the protease inhibitors phenylmethylsulfonyl chloride (PMSF) (200 pg/mL) and leupeptin (50 pg/mL) essentially as described previ~usly.~ Equal amounts of trichloroacetic acid precipitable counts were immunoprecipitated with 50 pL of normal rabbit (NRS), anti-kit rabbit sera,' or with 10 pL YB5.B8 ascites fluidI9 conjugated to protein A-sepharose beads (Pharmacia) for 90 Preparation and analysis ofRNA.
Flow cytometry.
Metabolic labeling and immunoprecipitation studies. minutes at 4°C. Protein A-sepharose beads were conjugated to rabbit antimouse serum (supplied by Dr Robert Knowles) before the application of YB5.B8. Immunoprecipitates with NRS or anti-kit serum were washed as previously described7 and YB5.B8 precipitates were washed three times in TNTG (20 mmol/L TRIS, 150 mmol/L NaCl, 0.1% Triton X-100, and 10% glycerol) at room temperature. All samples were resuspended in SDS sample buffer (62.5 mmol/L TRIS pH 6.8, 2% SDS, 2% mercaptoethanol, 10% glycerol, 50% bromphenol blue) boiled for 5 minutes, cleared, and supernatants analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (7.5%) and autoradiography. For reprecipitations, 15 p L of immunoprecipitate, denatured in SDWsample buffer, was diluted into 400 JLL of TNTG and then incubated with NRS or anti-kit serum-bound protein A-sepharose for 90 minutes at 4°C. Immune complexes were washed and analyzed by SDS-PAGE.
For preclearing experiments, YB5.B8 and an isotype-matched control antibody, 3D3.3 (anti~almonella),'~ were used. Solid-phase immunoprecipitation reagents were prepared by incubating 400 pL of either antibody (as culture supernatants) with 12.5 pL of antimouse Ig-conjugated sepharose or by incubating 8 p L of rabbit anti-kit serum or NRS (negative control) to 12.5 pL of protein-A sepharose (Pharmacia). NP40-lysates of surface biotinylated HEL cells were prepared as described previously?4 Lysate (500 pL) was cleared of antigen with four cycles of solid-phase immunoprecipitation (12. NP-40/TNE, and one time with TNE), denatured in SDS/sample buffer, subjected to 7.5% SDS-PAGE, and transferred to nitrocell~l o s e .~~ Biotinylated protein was detected after blocking with 3% bovine serum albumin using streptavidin biotinylated peroxidase complex (Amersham RNP.1051) followed by diaminobenzidine (DAB) with cobalt enhan~ement.3~
Immune complex kinase assay. Immune complex kinase assays were performed essentially as described previ0usly.3.~ HEL cells, lo7, were washed twice in PBS at 4°C and the cell pellet was resuspended in 1.2 mL HNTG lysis buffer (20 mmol/L HEPES, 150 mmol/L NaCl, 1% Triton X-100, 10% glycerol) containing 200 pg/mL PMSF and 50 &mL leupeptin and incubated for 30 minutes on ice. The lysate was then cleared by centrifugation at 12,OOOg for 10 minutes at 4°C. Two hundred microliters of the lysate diluted with an equal volume of HNTG/wash A (20 mmoVL HEPES, 150 mmol/L NaC1, 0.1% Triton X-100, 10% glycerol) was precipitated with NRS, anti-kit serum, rabbit antimouse Ig, or YBS.B&coated protein A-sepharose beads for 90 minutes at 4°C as described above. Immunoprecipitates were washed twice with HNTG/wash B (50 mmol/L HEPES, 500 mmol/L NaCI, 0.2% Triton X-loo), twice with HNTG/wash A, and once with 20 mmol/L PIPES, pH 7.2. All washes were performed at 4°C. Immunoprecipitates were then suspended in 30 pL of 20 mmol/L PIPES (pH 7.2), 10 mmol/L MnCI, 10 pmol/L ATP, and -y-"P-ATP (20 pCi/30 pL) and incubated for 10 minutes at 37°C. Kinase reactions were terminated by adding 7.2 pL 5X SDS/sample buffer, boiled, and analyzed by SDS-PAGE (7.5%) and autoradiography. Alkali treatment of gels was performed as described by Cooper et Murine KL was purified from Balb/c-3T3 fibroblasts as previously described' and iodinated by the chloramine T method as modified by Stanley and Guilbert3' to a specific activity of approximately 2.5 x lo5 cpm/ng KL. Binding assays were performed essentially as previously de~cribed?'~ Briefly, Cell surface expression of the YB5.B8 antigen in HEL, A172, and Ramos cells was examined by flow cytometry (Fig 3) . 
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. . Adsorption experiments were performed to further corroborate that YB5.B8 identifies the c-kit protein product. Immunoprecipitation of proteins from cell-surface biotinlabeled HEL cell lysates with the YB5.B8 antibody or with anti-kit serum resulted in identical 150-Kd bands of similar intensity (Fig 5, lanes 2 and 6) . For both antibodies, immunoprecipitation after four cycles of preclearing with control antibodies NRS or 3D3.3 resulted again in 150-Kd bands (Fig 5, lanes 5 and 9) . However, when lysates were precleared with four cycles of YB5.B8 or anti-kit, subsequent precipitation with these antibodies resulted in 150-Kd bands of markedly reduced intensity (Fig 5, lanes 3, 4, 7 , and 8). These results further support the notion that both YB5.B8 and anti-kit detect the same antigen on the surface of HEL cells.
Many antibodies to protein tyrosine kinases facilitate their autophosphorylation in immune complex kinase assays. Therefore, we determined whether YB5.B8, like the anti-kit serum, would facilitate c-kit autophosphorylation in an immune complex kinase assay. Immunoprecipitates were prepared from HEL cell lysates with YB5.B8, anti-kit serum, and normal rabbit serum, incubated with -'*P-ATP and manganese ions in a kinase reaction, and analyzed by SDS-PAGE. The results, shown in Fig 6, The rat c-kit ligand displays cross-species reactivity and facilitates the proliferation of human myeloid and lymphoid progenitors in bone marrow cultures. In agreement with these observations the murine c-kit ligand (mKL) was shown to bind to the c-kit expressing human HEL cells. The ability of YB5.B8 to block the binding of ligand to c-kit was tested by measuring its affect on the specific binding of mKL to HEL cells. HEL cells were preincubated at 4°C with purified YB5.B8 or control 3D3.3 antibody, 12%labeled mKL was added, and binding was measured after further incubation at 4°C. YB5.B8 blocked the specific binding of mKL to HEL cells in a dose-dependent manner with complete inhibition at 20 p g h L of antibody (Fig 7) . Little to no inhibition was seen with the control 3D3.3 antibody. This result provides further evidence that YB5.B8 identifies c-kit and suggests that it recognizes an epitope near or within the ligand binding domain of c-kit.
Expression of c-kit in AML and normal bone marrow. The MoAb YB5.B8 was raised against MI AML blasts, and the YB5.B8 antigen was shown to be exmessed on cells of a . part from serine phosphorylation. Fig 8) . Specimens from most French-American-British (FAB) classifications were represented in the group with increased expression; however, the one M, and all three M,b specimens were negative (Table. 1 ).
DISCUSSION
Previous work illustrated that the c-kit protein, the gene product of the murine W locus, and the antigen identified by the MoAb YB5.B8, share similar cellular distribution, topologic characteristics, and molecular eight.^."^^'^^^^^^ The experiments described here provide evidence that these entities are, in actuality, the same. The proof for identity is The YB5.B8 MoAb was raised against an M,-type AML. A previous survey of samples from a broad group of AMLs indicated YB5.B8 binding and therefore c-kit protein expression in 30% of AML specimens." The c-kit RNA expression studies reported here showed increased expression in 68% of 19 AML specimens. The discrepancy in percentages between the two studies may reflect a difference in cell source (peripheral blood v bone marrow), dissimilar sensitivities of the two detection methods used, and/or differential post-transcriptional controls in some and not in other AML samples. The results of these studies imply that certain FAB subclasses (particularly M, and M,b) may not express c-kit RNA or protein at an increased level; however, more extensive analyses are needed to explore this possibility. The increased expression of c-kit RNA and protein in AML may reflect an enlarged cell population corresponding to a particular stage in myeloid differentiation where c-kit is expressed normally. An analysis of c-kit/YBS.B8 expression in human progenitor cell populations and in myeloid cells at various levels of differentiation would be useful in investigating this possibility. An alternative explanation for increased c-kit/YB5.B8 expression in AML may be that c-kit is involved in the development and ultimate outcome of AML. Such a hypothesis would be in agreement with the finding that the YB5.B8 antibody identified a sub-group of AML patients with a diminished response to standard chemotherapy and poor survival?' At present no evidence exists for alterations in the human c-kit locus in AML;" however, a more extensive analysis examining the c-kit gene might show a subset of patients with gene rearrangements, deletions, amplifications, or point mutations. Future studies on the role of c-kit in AML should also explore the expression of KL in AML as well as its effects on the growth of leukemic blasts in culture.
